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Background: While it is now recognized that autism spectrum disorder (ASD) is typically a life-long condition, there
exist only a handful of systematic studies on middle-aged and older adults with this condition.
Methods: We first performed a structured examination of parkinsonian motor signs in a hypothesis-generating,
pilot study (study I) of 19 adults with ASD over 49 years of age. Observing high rates of parkinsonism in those off
atypical neuroleptics (2/12, 17 %) in comparison to published population rates for Parkinson’s disease and
parkinsonism, we examined a second sample of 37 adults with ASD, over 39 years of age, using a structured
neurological assessment for parkinsonism.
Results: Twelve of the 37 subjects (32 %) met the diagnostic criteria for parkinsonism; however, of these, 29 subjects
were on atypical neuroleptics, complicating interpretation of the findings. Two of eight (25 %) subjects not taking
atypical neuroleptic medications met the criteria for parkinsonism. Combining subjects who were not currently taking
atypical neuroleptic medications, across both studies, we conservatively classified 4/20 (20 %) with parkinsonism.
Conclusions: We find a high frequency of parkinsonism among ASD individuals older than 39 years. If high rates of
parkinsonism and potentially Parkinson’s disease are confirmed in subsequent studies of ASD, this observation has
important implications for understanding the neurobiology of autism and treatment of manifestations in older adults.
Given the prevalence of autism in school-age children, the recognition of its life-long natural history, and the
recognition of the aging of western societies, these findings also support the importance of further systematic study of
other aspects of older adults with autism.
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Autism spectrum disorder (ASD) is defined by the pres-
ence of characteristic behaviors present in early childhood
[1]. While it is now recognized that ASD is typically a life-
long condition, there exist only a handful of systematic
studies of middle-aged and older adults [2–4]. According
to the most recent estimate from the Centers for Disease
Control (CDC), the prevalence of ASDs in US children is
approximately 1.5 % [5]. Given the well-documented aging
of the population in western societies [6], we and others
have highlighted the need for increasing research efforts* Correspondence: jpiven@med.unc.edu
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this article, unless otherwise stated.into all aspects of ASD in the aging population, to address
what undoubtedly will be an important and increasing
public health issue [7].
To begin to examine ASD in older (i.e., relative to previ-
ous studies of ASD) individuals with ASD, several years
ago we began a pilot, descriptive study in North Carolina
(NC) of adults with ASD 50 years and older. This study
focused broadly across a range of domains—including
current autistic behaviors, medical/psychiatric/neuro-
logical problems, cognitive level, adaptive behavior, quality
of life, family/community support, and available services,
to inform ourselves about specific areas for more concen-
trated focus. As the project progressed, we observed what
appeared to be high rates of parkinsonian signs in our
ASD subjects (study I). We, therefore, sought to ascertain
a second sample of adults with ASD in which to conduct
a systematic assessment of parkinsonian signs (study II)ticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
mmons.org/publicdomain/zero/1.0/) applies to the data made available in
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“older” individuals with ASD had elevated rates of parkin-
sonian signs. We herein report the results from the exam-
ination of samples in studies I and II.
While systematic studies of Parkinson’s disease and
parkinsonism have not been conducted in adults with
ASD, a number of indirect and direct links between aut-
ism and Parkinson’s disease have been suggested in the
research literature. Hollander et al. [8] suggested links
between the two conditions based on overlapping phe-
nomenology in the area of repetitive behaviors, with a
common underlying involvement of the basal ganglia.
Links between autism and the basal ganglia have been
reported by a number of studies [9–11]. Recently, motor
system deficits have been suggested as having a core role
in ASD, based on the observation of motor dysfunction in
children, adolescents, and young adults [12–17]. Motor
deficits have been reported in infants prior to the typical
time for diagnosis of ASD [18–21], suggesting the possible
primacy of the motor system in autism. Overlap has also
been noted in genetics, where the Park2 gene, implicated
in Parkinson’s disease, has also been found in association
with ASD [22]; Park2 copy number variant mutations
have been identified in case reports of children with
Asperger syndrome [23]; and mutations have been identi-
fied in a gene-regulating dopamine metabolism and be-
havioral responses to dopaminergic drugs, also implicated
in Parkinson’s disease [24]. Establishing a precedent that
genes linked to neurodevelopmental disorders also play a
role in late-life neurodegenerative conditions, the link be-
tween the fragile X pre-mutation and parkinsonism, as
expressed in the fragile X associated tremor and ataxia
syndrome (FXTAS), is now well established [25–27].
In the present report, we systematically examine the
relationship between parkinsonian signs and ASD in
middle-aged and older adults. In study I, we conduct an
exploratory study in 19 adults with ASD, over 49 years of
age. In study II, we follow up a hypothesis generated from
study I, systematically assessing 37 adults with ASD, over
39 years of age, for evidence of parkinsonian signs.
Methods
The initial, pilot study was conducted at the University
of North Carolina (Chapel Hill) (NC). A replication




Inclusion criteria for the study were (1) ≥50 years of age,
(2) a clinical diagnosis of ASD, and (3) an informant able
to provide historical information about the participant.
DSM-5 diagnosis of ASD was confirmed by clinical best
estimate (JP) after review of the Autism DiagnosticInterview (ADI) [28], the Autism Diagnostic Observation
Schedule (ADOS) [29], and all available information
from medical records. The Institutional Review Board
(IRB) at the University of North Carolina (Chapel Hill)
approved this study. All subjects or their legal guardians
provided informed, written consent.
Ascertainment efforts were conducted through multiple
sources throughout North Carolina. Attempts were made
to contact 14,132 individuals with ASD through mailings
to the Autism Society of North Carolina (N = 14,034),
record review of the Treatment Education of Adults and
Children with Autism and other Communication Handicaps
(TEACCH) program seen over the last 40 years (N= 24
contacted), NC state residential facilities for adults with
developmental disabilities (N = 24 contacted), the UNC
Autism Registry of the Carolina Institute for Developmen-
tal Disabilities (N = 17 contacted), outpatient attendance
at the University of North Carolina Hospitals and Clinics
(N = 14 contacted), and a large general medical practice
that specifically cares for adults with developmental dis-
abilities living in “intermediate care facilities for individ-
uals with mental retardation (ICFMR)”, in North Carolina
(N = 9 contacted). Overall, 30 individuals with ASD or
their guardians consented to participate in the study.
Three individuals declined participation after the screen-
ing process, due to time constraints, and eight were ex-
cluded after enrollment based on insufficient evidence
supporting a DSM5 diagnosis of ASD. The final sample




Inclusion criteria for the study were (1) ≥40 years of age,
(2) a clinical diagnosis of ASD, and (3) an informant able
to provide historical information about the participant.
DSM-5 diagnosis of ASD was confirmed by clinical best
estimate (SES) after review of the ADI [28], the ADOS
[29], and all available information from medical records.
The South Metropolitan Health Service Human Research
Ethics Committee approved this study. All subjects or
their legal guardians provided informed written consent.
Subjects were recruited from two sources: (1) a list pro-
vided by the Disabilities Services Commission of Western
Australia (DSC) which included 46 individuals 40 years or
older with a diagnosis of ASD and (2) a list of 24 individ-
uals with a diagnosis of ASD, 40 years or older, who had
attended the Psychiatry Clinic at the Autism Association
(AA) of Western Australia during the first 10 months of
2014. The DSC provides services to all registered individ-
uals diagnosed with ASD in WA. The Psychiatry Clinic at
the AA is the only clinic in WA specialized in assessing
and managing challenging behaviors in adults with ASD.
Individuals with ASD and/or their respective caregivers
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individuals from the DSC list consented to participate. All
29 completed the assessment protocol. Of the 17 individ-
uals who did not participate in the study, 13 refused to
participate or did not return a signed consent form, and
four could not be contacted. Eleven of the 24 individuals
with ASD from the AA Psychiatry Clinic list consented to
participate, and eight completed the assessment protocol
(assessments were not finalized on three subjects due to
loss of contact or job commitments). Of the 13 individuals
who did not participate, five refused or did not return a
signed consent form, and eight could not be contacted.
Assessment
All subjects and/or their informants were interviewed
with a structured assessment for demographic informa-
tion and medical history. Cognitive level (IQ group) was
derived from scores available through medical records.
When valid IQ estimates were not available, estimation
of IQ group was based on administration of one of three
measures of cognitive level or adaptive functioning: the
Wechsler Abbreviated Scale of Intelligence [30], the
Shipley-2 Scale [31], or the Vineland Adaptive Behavior
Scales [32], depending on level of subject cooperation/
ability. For the analyses, we collapsed cognitive scores
into two groups (IQ ≥50 and <50). For study I, motor
signs were assessed with the Unified Parkinson’s disease
Rating Scale (UPDRS) [33] by research assistants (LP,
MP) trained at the UNC Neurology Clinic by a board
certified neurologist and expert in degenerative neuro-
logical disorders (Daniel Kaufer, M.D.) and supervised
by a psychiatrist (JP). The UPDRS is a reliable and valid
instrument for assessing the severity of motor signs as-
sociated with Parkinson’s disease. A limitation of the
UPDRS for use in this population is that individuals with
moderate to severe comprehension deficits may not be
able to perform some of the tasks assessing bradykinesia
(e.g., items 23 to 26) or their limited comprehension
may make them unsuitable for valid testing of postural
stability. Therefore, a modification was used whereby
final clinical judgment on the presence of bradykinesia
was based on scores rating limb bradykinesia (items 23,
24, 25, and 26) and/or scores on body bradykinesia and
hypokinesia (item 31) (i.e., total bradykinesia was rated
based on the presence of body bradykinesia only when-
ever assessment of limb bradykinesia was not feasible).
For study II, motor signs were assessed with the Move-
ment Disorders Society-Unified Parkinson’s disease Rat-
ing Scale (MDS-UPDRS) (an updated and expanded
version of the UPDRS) by a neuropsychiatrist with ex-
tensive experience in assessing and diagnosing individ-
uals with Parkinson’s disease (SES, a neuropsychiatrist
with extensive experience in rating parkinsonism in
complex patients, such as older adults with psychosis,dementia, or severe depression). As with the UPDRS, a
limitation of the MDS-UPDRS for use in this population
is that individuals with moderate to severe comprehen-
sion deficits may not be able to perform some of the
tasks assessing bradykinesia (e.g., items 3.4 to 3.8) or
postural stability. Therefore, a modification was employed
whereby final clinical judgment on the presence of brady-
kinesia was based on scores rating limb bradykinesia
(items 3.4 to 3.8) and/or scores rating global spontaneity
of movement (item 3.14) (i.e., total bradykinesia was rated
based on the presence of body bradykinesia only whenever
assessment of limb bradykinesia was not feasible).
For both studies, motor signs were considered to be
present whenever the participant scored 2 or higher on
the respective UPDRS or MDS-UPDRS item. Thus, if a
score of 2 or more was given to one or more of the items
rating tremor, rigidity, bradykinesia, or postural problems,
the sign was rated as present. Scores of “1” (i.e., slight or
mild) were considered absent (and collapsed with scores
of “0”). Diagnosis of parkinsonism was made using the
Queen Square Brain Bank Criteria for idiopathic Parkinson’s
disease, based on UPDRS findings [34]. We followed step 1
of the diagnostic criteria for “Parkinsonian syndrome” which
requires the presence of bradykinesia and at least one of the
following: (1) rigidity, (2) 4–6-Hz resting tremor, or (3) pos-
tural instability.
Statistical analysis
Statistical analysis was carried out using means and stand-
ard deviations and t tests for between-group comparisons.
Associations appearing in frequency distributions were
tested using a Chi-square test (with Yates’ correction for
cell sizes <5). All p values are two-tailed, with the alpha
value equal to 0.05. Chlorpromazine equivalent estimates
were calculated based on the Woods algorithm [35].
Results
Study I
Study I included 19 males, with an average age of
57 years. Eleven (58 %) had IQ’s below 50; nine (47 %)
lived in residential facilities for adults with developmen-
tal disabilities, four (19 %) lived in-group homes, four
lived independently with support, and one (5 %) lived in-
dependently in the community (Table 1).
The frequency of occurrence of the cardinal signs for
parkinsonism were 22 % (N = 4) with bradykinesia, 16 %
(N = 3) with resting tremor, 32 % (N = 6) with rigidity,
and 15 % (N = 2) with postural instability (Table 2). As-
sessments of postural instability and bradykinesia were
difficult to conduct in six subjects and one subject, re-
spectively, and these ratings were not further considered.
There were no significant group differences between
subjects in the higher and lower IQ groups (i.e., less than
or ≥50) on resting tremor (χ2 = 2.59, df = 1, p = 0.11),
Table 1 Demographics
Study I (NC) Study II (WA)
Sample size/gender 19 males 32m/5f
Age: mean (SD) years 57 (6.7) 51.2 (8.5)
Range years 50–77 40–71
Education
No school/grade school 47 % 92 %
High school or equivalent 47 % 8 %
Post high school 6 % 0 %
IQ group
≥80 21 % 5 %
50–79 21 % 14 %
35–49 16 % 14 %
≤35 42 % 67 %
Living situation
Independent 5 % 11 %
Independent with support 21 % 0 %
With family (parents) 5 % 8 %
Group home 21 % 81 %
Residential facility 47 % 0 %
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0.06, df = 1, p = 0.80), or postural instability (χ2 = 0.13,
df = 1, p = 0.72) (Table 3). No significant differences
were noted between subjects currently on atypical neu-
roleptics (referred to as “neuroleptics”) (N = 7) com-
pared to those not on neuroleptics (N = 12) on the
presence of resting tremor (χ2 = 0.02, df = 1, p = 0.89),
rigidity (χ2 = 0.65, df = 1, p = 0.42), bradykinesia (χ2 =
0.42, df = 1, p = 0.52), or postural instability (χ2 = 0.71,
df = 1, p = 0.40) (Table 4; Table 5).
Three of the 19 subjects (16 %) met the criteria for
parkinsonism. Twelve of the 19 subjects (63 %) were not
on neuroleptic medication. Two subjects (17 %) also had
an independent (no knowledge of aims or goals of this
study) diagnosis of Parkinson’s disease made by a
community-based neurologist. One was on levodopa
treatment at the time of the assessment and the second
was recommended to take levodopa (see description in
Appendixes 1 and 2).Table 2 Frequency of Parkinsonian signs
Motor signs Study I Study II
% (N) % (N)
Resting tremor 16 (3) 19 (7)
Rigidity 32 (6) 19 (7)
Bradykinesia 22 (4)a 46 (17)
Postural instability 15 (2)a 19 (7)
aOne subject in study I could not be assessed for bradykinesia (total available
N = 18); six subjects in study I could not be assessed for postural instability
(total available N = 13)Study II
Study II included 32 males and 5 females, with an aver-
age age of 51 years. Thirty subjects (81 %) had an IQ
below 50. Thirty-one (84 %) lived in a group home, four
(11 %) lived independently in the community, and three
(8 %) lived with their families (Table 1).
The frequency of occurrence of the cardinal signs for
parkinsonism were 46 % (N = 17) with bradykinesia,
19 % (N = 7) with resting tremor, 19 % (N = 7) with rigid-
ity, and 19 % (N = 7) with postural instability (Table 2).
There were no significant group differences between
subjects in the higher and lower IQ groups (i.e., less than
or ≥50) on resting tremor (χ2 = 0.52, df = 1, p = 0.46), ri-
gidity (χ2 = 0.52, df = 1, p = 0.46), bradykinesia (χ2 = 0.01,
df = 1, p = 0.98), or postural instability (χ2 = 0.12, df = 1,
p = 0.72) (Table 3). There were no significant differences
between subjects on neuroleptics (N = 29) as compared
to those not on neuroleptics (N = 8) on presence of rest-
ing tremor (χ2 = 2.38, df = 1, p = 0.12), rigidity (χ2 = 2.38,
df = 1, p = 0.12), bradykinesia (χ2 = 0.29, df = 1, p = 0.58),
or postural instability (χ2 = 0.24, df = , p = 0.61) (Table 4).
Twelve of the 37 subjects (32 %) met the diagnostic
criteria for parkinsonism. Twenty-nine of the 37 subjects
(78 %) were currently on neuroleptic medication. Ten of
the 29 subjects on neuroleptics (34 %) met the criteria
for parkinsonism. Eight of the 37 subjects (22 %) were
not taking neuroleptic medication. Two (25 %) of these
eight subjects met the criteria for parkinsonism. During
the course of the study, these two individuals were re-
ferred to the Movement Disorders Clinic at Fremantle
Hospital due to motor problems impacting upon their
ability to complete basic activities of daily living. An in-
dependent diagnosis of Parkinson’s disease was made in
both subjects by a community neurologist (see descrip-
tion in the Appendixes 1 and 2). Given the substantial
number of subjects receiving neuroleptic medications,
we examined group differences in level of chlorpromaz-
ine equivalents (an algorithm based on the potency of a
specific medication and dose) [35] in those currently
taking and not taking these medications. There were no
significant differences in mean level of chlorpromazine
equivalents between subjects classified with and without
Parkinsonism-1 (mean mg ± SD: no PS-1 = 474 ± 758;
PS-1 = 246 ± 220; t = 1.01, df = 35, p = 0.31).
Studies I and II
Given the small number of subjects not currently on
neuroleptic medication in each study, samples were com-
bined (N = 56) with the aim of providing the best estimate
of the rate of parkinsonism in this adult ASD population.
The mean age of the combined sample of the 20 sub-
jects not on neuroleptics was 55.6 ± 8.6 (years ± SD),
range 42–77 years. All subjects were male. Four sub-
jects (20 %) received a diagnosis of Parkinson’s disease
Table 3 Frequency of Parkinsonian signs by IQ group
Motor signs % (N) Study I Study II
IQ group IQ group
≥50 (N = 8) <50 (N = 11) ≥50 (N = 7) <50 (N = 30)
Resting tremor 0 (0) 27 (3) 29 (2) 17 (5)
Rigidity 50 (4) 18 (2) 29 (2) 17 (5)
Bradykinesia 25 (2) 20 (2)a 43 (3) 57 (17)
Postural instabilitya 13 (1) 20 (1)a 14 (1) 20 (6)
aOne subject, with an IQ score less than 50, in study I could not be assessed for bradykinesia (total available N = 10); six subjects with IQ scores less than 50 in
study I could not be assessed for postural instability (total available N = 5)
Table 5 To provide additional descriptive data on the
frequency of combined parkinsonian signs within individuals,
below, we list individuals by the various combinations of
parkinsonian signs
Number of
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levodopa (N = 1). Available information documented that
none of these four subjects had been given a neuroleptic
medication in the previous 5 years (and perhaps longer,
but sufficient documentation was not available to make a
statement about a longer period of time in all four sub-
jects). There was no significant difference in rate of parkin-
sonism (4/20 subjects, or 20 %) in this group versus the
11/36 subjects (31 %) from the combined study group who
were on neuroleptics (χ2 = 0.52, df = 1, p = 0.46). A signifi-
cantly greater number of subjects were on neuroleptics
in study II (78 %) than in study I (37 %) (χ2 = 7.71, df =
1, p = 0.006).
Discussion
In this paper, high rates of parkinsonism are reported in
a sample of 19 adults with ASD over 49 years of age,
who were directly examined, characterized on a struc-
tured rating scale, and diagnosed according to the stan-
dardized diagnostic criteria. These findings were then
replicated in an independent sample of 37 adults with
ASD over age 39. After excluding subjects currently on
neuroleptic medications, the frequency of occurrence of
parkinsonism was 20 % in the combined sample and 17
and 25 %, in each sample, respectively. Four patients (7 %
of the combined sample) were diagnosed with PD by com-
munity neurologists. In two patients, the diagnosis shouldTable 4 Frequency of Parkinsonian signs by current neuroleptic
treatment
Motor signs % (N) Current medication treatment
Study I Study II
Yes (N = 7) No (N = 12) Yes (N = 29) No (N = 8)
Resting tremor 14 (1) 17 (2) 24 (7) 0
Rigidity 43 (3) 25 (3) 24 (7) 0
Bradykinesia 14 (1) 27 (3)a 48 (14) 38 (3)
Postural instability 0a 20 (2)a 17 (5) 25 (2)
aOne subject who does not currently take neuroleptic medication in study I
could not be assessed for bradykinesia (total available N = 11), three subjects
currently taking neuroleptic medication could not be assessed for postural
instability (N = 4), and three subjects who are not currently taking medication
in study I could not be assessed for postural instability (total available N = 9)be considered tentative—one was on levodopa and while
they met the criteria for parkinsonism, they had no expli-
cit diagnosis of PD in the medical record, whereas the sec-
ond patient met the diagnostic criteria for parkinsonism
and was diagnosed as having “lower limb parkinsonism.”
The findings from this study suggest high rates of
parkinsonism among ASD individuals over 39 years of
age. The rate of parkinsonism in the general population
aged 65–70 has been estimated at 0.9 % [36], as com-
pared to 27 % in our combined total sample and 20 %
when subjects on atypical neuroleptics were excluded. It
is important to note that the de Rijk et al. [36] study in-
cluded individuals with drug-induced parkinsonism in
their parkinsonism group, making the comparison even
more conservative (as those subjects were excluded from
the current study). Moreover, in the current study, par-
kinsonism was only diagnosed when it occurred together
with bradykinesia (a required criterion), whereas in the
de Rijk et al. [36] study, parkinsonism was diagnosed if
any two of the four cardinal symptoms for PD were
present. Furthermore, the rates observed in the presentsubjects
Signs present Study 1 Study 2
Tremor + rigidity + bradykinesia + postural instability 0 1
Tremor + rigidity + bradykinesia 1 3
Postural instability + bradykinesia 1 5
Tremor + bradykinesia 0 2
Rigidity + bradykinesia 0 1
Postural instability + rigidity 1 0
Tremor + rigidity 1 1
Rigidity only 2 1
Bradykinesia only 1 5
Tremor only 1 1
Postural Instability only 1 0
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rate for Parkinson’s disease in the general population 40
to 60 years of age [37].
The estimates in the current study are conservative in
that, in order to maximize accuracy in classifying affected
individuals, we used a cutoff of ≥2 when rating the UPDRS
and MDS-UPDRS and ratings of 1 were collapsed with rat-
ings of “0” (i.e., rated as “absent”). We view this as a conser-
vative approach that may have led to several false negative
classifications (see Appendixes 1 and 2 for clinical examples
and further clarification). In addition, rates of parkinsonism
were based on the entire sample of subjects in each study
group, although a substantial portion of subjects in both
groups were unable to be rated on signs that required active
participation (e.g., finger tapping to rate bradykinesia and
postural instability among non-verbal subjects).
The observation that the frequency of motor signs did
not differ between those subjects currently taking neuro-
leptic medications versus those not on such medications,
as well as the observation that parkinsonism was undimin-
ished in several subjects on successively lowered doses of
atypical neuroleptics, suggests the possibility that some
cases of parkinsonism, observed in individuals on neuro-
leptics, may have been misclassified as being secondary to
medications, when in fact they may have had a primary
parkinsonism. In the Appendixes 1 and 2, we describe
motor signs in a subject whose motor abnormalities were
not improved on decreasing and ultimately discontinued
(for 4 months as of the time of this submission) doses of
olanzapine. In conclusion, it is highly likely that we may
have under-estimated the true frequency of both PD and
parkinsonism in ASD, which may be higher than herewith
reported.
The process of diagnosing Parkinson’s disease in ASD
is complex for several reasons: (1) As we found in this
study, many adults with ASD are or have been on neuro-
leptic medication. (2) ASD has its own motor idiosyn-
crasies, such as motor stereotypies, generic “clumsiness,”
and dyspraxia, which complicate the neurological exam.
(3) Non-verbal ASD subjects are difficult to assess with
the UPDRS/MDS-UPDRS, given that some of them are
unable to follow commands. (4) Given that many adults
with ASD live in-group homes or other supported accom-
modations, with a high turnover of caregivers, information
about whether parkinsonian signs are progressive, with
persistent asymmetry or had a unilateral onset, cannot al-
ways be ascertained. This limitation makes it difficult to
use step 3 criteria of the UK Parkinson’s disease Society
Brain Bank Clinical Diagnostic Criteria for a definitive
diagnosis of Parkinson’s disease. We provide clinical vi-
gnettes in the Appendixes 1 and 2 that illustrate several
of the complexities we encountered in our efforts to
classify these individuals relative to the presence or ab-
sence of Parkinson’s disease.An important limitation of this set of studies was the
absence of local control groups for direct comparison of
rates of parkinsonism and Parkinson’s disease. The lack
of a systematic ascertainment scheme in study I pre-
cluded the identification of a suitable comparison group.
While ascertainment in study II was done more system-
atically, lack of sufficient funding for that study pre-
cluded the addition of a comparably ascertained and
assessed contrast group. Nevertheless, we believe that
there is no evidence that either study was biased towards
recruiting subjects with movement disorders, and the
comparable rates observed in the two independent sam-
ples examined raises confidence in the validity of the
findings. In addition, there was no evidence that poten-
tial confounding factors (e.g., low IQ or living in a long-
term residential care facility) explained the rates of
parkinsonism observed, as rates in the high and low IQ
groups and between those living in residential care and
others did not differ significantly.
The proportion of subjects with low IQ in both studies
was considerably higher than current population esti-
mates based on epidemiologically ascertained samples of
school-aged children with autism [5]. A likely reason for
this is that the rates of low IQ in the current sample are
a reflection of ascertainment characteristics in childhood
autism samples of the 1960s and 1970s, when many of
the subjects in this study were diagnosed. It is possible
that many higher functioning children with autism in
the 1960s and 1970s were either undetected or misdiag-
nosed and continue to be under-recognized as adults,
resulting in the difficulties we encountered in finding
adults with ASD over 50 in the North Carolina sample
and the higher proportion of subjects with low IQ ascer-
tained in both study groups. This possibility is supported
by findings from Mandell et al. [38], where 10 % of
adults with autism in a state psychiatric hospital were
found to be misdiagnosed with schizophrenia and other
psychiatric conditions. Finally, accurate calculation of IQ
scores in adults with ASD was an additional problem en-
countered in this study. IQ was estimated in some cases,
from the Vineland adaptive behavior composite. Given
that most of these participants live in-group homes with
restrictive policies regarding activities (e.g. cooking, trav-
eling independently), individuals with higher capacity
and skills may have been inadvertently penalized with
relatively lower scores.
While the findings from these two studies suggest a
relationship between ASD and Parkinson’s disease, we
can only speculate on the underlying explanation for this
observed relationship. Several possibilities exist. First,
given the relatively small size and the lack of a population-
based ascertainment of both study groups, an unknown
ascertainment bias must be considered as a possible ex-
planation. Second, while current medication use did not
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study, it is possible that long-term neuroleptic use and an
underlying increased sensitivity to those medications may
have had the effect of increasing the risk for parkinsonism
later in life (even in those now off such medications).
Thus, future studies should assess lifetime exposure to
neuroleptic medication and examine the possibility that
individuals with ASD, exposed to neuroleptics during
their lifetime, may be at increased risk of developing
Parkinson’s disease in mid- and later-life. A third possi-
bility is that neuroleptic use may have “unmasked” a
pre-clinical stage of Parkinson’s disease, perhaps lower-
ing the threshold for dopamine loss in the development
of Parkinson’s disease [39]. This hypothesis warrants
examination in longitudinal studies of younger popula-
tions, as well as in older populations where better his-
torical information is available.
Of greatest interest is a fourth possibility, that ASD
and Parkinson’s disease share a common underlying
pathogenetic mechanism or mechanisms that have both
early and later manifestations. This idea is reminiscent
of the early effects of the expanded triplet repeat in the
FMR1 gene in causing both fragile X syndrome in chil-
dren and the later effects of the FMR1 pre-mutation in
causing fragile X-associated tremor and ataxia in carrier
grandfathers in their fifth and sixth decades of life [25].
Parkinson’s disease may itself be a syndrome with mul-
tiple etiologies, some of which may be shared with ASD.
The findings from these studies, linking ASD and PD,
have potential implications for understanding the neuro-
biology of both conditions. Links between the two have
been made previously based on overlapping phenomen-
ology and neurobiology [8]. Motor stereotypies are a
well-known feature of ASD in a subset of individuals
with autism [40], and an emerging literature suggests
that a variety of other types of motor deficits (e.g., pos-
tural control, precision grip, and motor learning) are
present at high rates in individuals with autism [12–17,
41–43]). Making observations of motor impairment in
siblings and twins concordant and discordant for autism,
Hilton et al. [44] have suggested that motor impairment
constitutes a core characteristic of autism and that it is
influenced by genetic factors. Also of interest is the rela-
tively recent observation in high risk infant studies that
gross motor deficits in the first year of life appear to pre-
cede the appearance of social deficits in the latter part of
the first and second years, in high risk infants who go
on to develop ASD [19–21]. Motor deficits in infancy
have also been observed in retrospective, videotape ana-
lyses of individuals with autism [18]. Together these
findings suggest a more primary and fundamental role
of motor dysfunction in the pathogenesis of autism.
Common biological underpinnings between autism and
Parkinson’s disease have also been suggested. Consistentwith the behavioral observations of deficits in motor func-
tion in autism, brain abnormalities have been reported in
individuals with autism and mouse models of autism, in
regions and structures linked to the motor system. Struc-
tural imaging studies have noted abnormalities in the
striatum [9–11, 45] and resting state functional abnor-
malities in primary motor cortex [46]. The cerebellum
has also been implicated as playing a role in Parkinson’s
disease pathophysiology [47], is known to be intercon-
nected to the basal ganglia [48], and has been noted to
be abnormal in individuals with autism on postmortem
examination [49, 50]; brain imaging [51, 52], rapid pre-
cision grip [53], and in mouse models of the disorder
[54, 55]. Genetic links between PD and autism have
also been suggested by molecular studies identifying a
mutation in Parkinson disease-associated, G-protein-
coupled receptor in a number of unrelated autistic indi-
viduals [24]. Finally, the finding of high rates of parkin-
sonism in pre-mutation carriers of the fragile X
mutation who manifest signs of FXTAS [25–27] sug-
gests a possible common underlying biology in the sub-
set of individuals with autism who go on to have
Parkinson’s disease in later life. The molecular signaling
pathways involved in fragile X (e.g., phosphoinositide 3-
kinase or PI3-kinase and mammalian target of rapamy-
cin or mTOR) lay at the confluence of molecular sig-
naling pathways underlying several other genetically
defined autistic syndromes (e.g., Rett Syndrome, PTEN,
and tuberous sclerosis) and have been implicated in
Parkinson’s disease [56–58]. While specific biological
mechanisms underlying the possible relationship between
Parkinson’s disease and autism remain to be explored,
identifying those individuals with parkinsonism in adult-
hood is a reasonable a strategy to explore in identifying a
more etiologically homogenous subgroup with autism
than those with idiopathic autism.
The possibility that individuals with autism are at in-
creased risk for Parkinson’s disease as adults has import-
ant implications for detection and assessment, clinical
practice, systems of care, training, and public policy.
While research on ASD is now underway in young adult
populations, the striking absence of research on autism
in “older” adults has been noted in the literature [7].
This dearth of knowledge about the problems faced by
this population is likely to have a serious impact on fu-
ture quality of care, with the increasing demands for
care associated with the dramatic aging of western soci-
eties. The finding of high rates of Parkinson’s disease in
older adults with autism is likely to be only one of many
potential new findings to be discovered, as the research
community turns its attention to this relatively neglected
population. Such findings will have important implica-
tions for building capacity to care for such individuals,
as it is likely that there will be unique aspects of their
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the present study are confirmed, there will be a need to
understand the underlying pathogenesis of parkinsonism
and Parkinson’s disease in ASD, to examine co-occurring
behavioral and other features of the condition and to
explore potential differences in treatment from the trad-
itional approaches to Parkinson’s disease in individuals
without ASD. Our finding of a high frequency of parkin-
sonism among middle-age and older autistic individuals
on atypical neuroleptics emphasizes the urgent need to
clarify whether there is a subset of individuals with ASD
at a high risk for developing movement disorders, as well
as exploring the possibility that neuroleptic medications
may unmask or precipitate true Parkinson’s disease in
older individuals with ASD. As a more general observa-
tion, the vast majority of the subjects we detected who
had parkinsonism and were on neuroleptic medications,
had motor deficits not appreciated by their care providers
or noted in the medical records. Failure to recognize
drug-induced parkinsonism in the elderly is well described
[59], and it is possible that recognition may be even lower
in elderly with ASD. Co-morbid dementia may compli-
cate a diagnosis of Parkinson’s disease, but none of our
subjects had a history of functional decline or stepwise
deterioration.
The lack of controls in both studies and ascertainment
scheme in study I have been noted above as limitations
of this work. There were also differences between studies
in level of education, IQ, and living arrangements that
may have had an unknown impact on the findings. An-
other limitation was that only 22 % of patients in study
2 were neuroleptic free, as compared to 63 % in study 1.
These findings suggest that a relatively high percentage
of adults with ASD will be on neuroleptic medication
and/or will have a history of neuroleptic intake. This will
be an important confounder for future studies aiming at
ascertaining representative samples of adults with ASD
off neuroleptics. The safety of withdrawal of neuroleptics
among ASD individuals with well-controlled challenging
behaviors remains unknown. A better option could be
using DaTscan studies, a functional technique of imaging
the dopamine transporter that helps to determine pre-
synaptic dopamine neuronal degeneration [60]. DaTscan
studies may help distinguishing neurodegenerative from
drug-induced parkinsonism, although false-positive re-
sults in drug-induced parkinsonism has been reported
[61]. Other limitations included the lack of establishment
of inter-rater reliability within and across studies, although
good reliability of the UPDRS and MDS-UPDRS has been
demonstrated [33, 62], limited information on life-long
medication history and, for a number of subjects, limited
information about early childhood behavior (to provide
more certainty of diagnosis). Our relatively small sample
size may account for the lack of significant differences infrequency of parkinsonism between ASD individuals on
vs. off neuroleptics, as well as the lack of significant associ-
ation between parkinsonism and clinical variables such as
IQ. In addition, while it seems unlikely to be an explan-
ation of the findings from the present studies, there is a
possibility that some affected subjects had fragile X syn-
drome co-occurring with their ASD, as the presence of
the fragile X mutation is known to account for a small
portion of cases of ASD, and the FMR1 pre-mutation
has been linked to risk for Parkinsonian motor deficits
[27, 63]. Future studies of Parkinson’s disease and parkin-
sonism in older adults with ASD should rule out the pres-
ence of the fragile X mutation in their study subjects.
Conclusions
We find a high frequency of parkinsonism among ASD
individuals older than 39 years. If high rates of parkin-
sonism and potentially Parkinson’s disease are confirmed
in subsequent studies of ASD, this observation has im-
portant implications for understanding the neurobiology
of autism and treatment of manifestations in older adults.
Given the prevalence of autism in school-age children,
the recognition of its life-long natural history, and the
recognition of the aging of western societies, these find-
ings also support the importance of further systematic
study of other aspects of older adults with autism.
Appendix
To maximize confidentiality, demographic information
was not included in the vignettes below. For the follow-
ing vignettes, we employ the following scoring conven-
tion: (1) UPDRS: 0 = absent; 1 =mild; 2 = moderate; 3 =
severe, 4 = unable to perform task; (2) MDS-UPDRS: 0 =
absent, 1 = slight, 2 = mild, 3 =moderate, 4 = severe.




On the UPDRS, this subject had moderate resting and
action tremor in both upper limbs; moderate rigidity in
the right upper limb, marked rigidity in the left upper
limb, and severe rigidity in both lower limbs; marked bi-
lateral bradykinesia on hand movements; moderate def-
icit on arising from chair; moderately stooped posture;
shuffling gait; mild postural instability; and moderate
body bradykinesia (note: finger tapping, rapid alternating
movements, and leg agility could not be assessed due to
poor comprehension/cooperation). Total UPDRS motor
score was 38 (note: total score refers to the cumulative
score across individual items appearing in section 3 of
the UPDRS/MDS-UPDRS). Subject 1 was on carbidopa/
levodopa 250 mg t.i.d started by a neurologist independ-
ent of the study.
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On the UPDRS, this subject showed mild resting tremor
in the right upper limb; mild rigidity of the neck and the
right lower limb; mild stooped posture; marked shuffling
gait; marked absence of postural reflexes; and moderate
body bradykinesia (note: hand movements and rapid al-
ternating movements could not be tested due to poor
comprehension/cooperation). Total UPDRS motor score
was 12. An independent neurology report indicated that
symptoms were consistent with “gait predominant Parkin-
sonism” and that a trial treatment with Sinemet “might be
beneficial.” The subject was not receiving this treatment at
the time of the study.
Study II
Subject 3
On the MDS-UPDRS, this subject showed slight bilateral
kinetic tremor, slight bilateral bradykinesia on finger tap-
ping, mild bradykinesia on hand movements in the right
upper limb, and moderate bradykinesia of the left upper
limb. He had slight bradykinesia on pronation-supination
of the right hand and moderate bradykinesia of the left
hand, slight bilateral bradykinesia on both toe tapping and
leg agility; mild shuffling gait; absence of postural re-
sponse; moderate stooped posture; and mild body brady-
kinesia. Total MDS-UPDRS motor score was 28. This
individual was diagnosed with Parkinson’s disease by a
neurologist independent of the study. He was recently
started on levodopa (100 mg tds) with marked improve-
ment on upper limb tremor.
Subject 4
On the MDS-UPDRS, this subject showed mild bilat-
eral bradykinesia on finger tapping, hand movements,
pronation-supination movements of hands, toe tapping,
and leg agility; slight slowness arising from a chair; slight
shuffling gait; absence of postural response; and mild body
bradykinesia. Total MDS-UPDRS motor score was 28.
This individual was diagnosed with Parkinson’s disease by
a neurologist independent of the study but was not on
levodopa at the time of the assessment.
Possible false negative classification
We conservatively considered scores of 1 on the UPDRS/
MDS-UPDRS (i.e., slight or mild) as 0 (i.e., “absent”). The
rationale for this was to increase certainty in ratings of
motor signs deemed to be “present” and concerns about
reliability of ratings of “1.” However, we believe in some
cases this may have led to false negative classification. Spe-
cifically, several subjects not on neuroleptics were rated a
1 on items involving multiple measurements (such as
“rigidity” involving multiple limbs) or had evidence of car-
dinal signs that were measured in multiple ways (e.g., mul-
tiple items for bradykinesia), but all ratings were 1.Regardless of the consistency across items or measure-
ments within a single domain, a rating of 1 was always
rated as equivalent to “absent”. An example is provided
below:
Subject A
On the UPDRS, this subject showed severe neck rigidity,
marked rigidity in the right upper and lower limbs, and
slight rigidity on the left lower limb. He was also rated
as having mild bilateral bradykinesia in the upper limbs
on rapid alternating movements, mild slowness in
arising from a chair, slightly stooped posture, moderate
difficulty in walking due to a shuffling gait, and mild
postural instability. Total UPDRS motor score was 21.
ASD subject with parkinsonian syndrome, on neuroleptics
at the time of assessment
The subject below met criteria for Parkinsonian syn-
drome; but was on neuroleptic medication (olanzapine
7.5 mg/day).
Subject B
On the MDS-UPDRS, this subject showed mild postural,
kinetic, and resting tremor of the right upper limb and
moderate postural, kinetic, and resting tremor of the left
upper limb; mild rigidity in the neck, both upper limbs,
and the right lower limb; mild bilateral bradykinesia on
finger tapping, hand movements, pronation-supination
of hands, toe tapping, and leg agility; slight slowness on
arising from a chair; slight shuffling gait; absence of pos-
tural response; moderate stooped posture; and moderate
body bradykinesia. Total UPDRS motor score was 56.
Olanzapine was slowly reduced and ceased, but at 4-month
follow-up, parkinsonian signs remained unchanged.
Scoring system
Tremor assessment is divided into (1) postural tremor of
the hands and (2) kinetic tremor of the hands (which is
tested by the finger-to-nose maneuver) and rest tremor
amplitude (this includes tremor that may appear at any
time during the exam, including when quietly sitting, dur-
ing walking, and during other bodily movements). Score
range from normal (score = 0) to severe (score = 4).
Rigidity is judged on slow passive movement of major
joints with the individual in a relaxed position and the
examiner manipulating the limbs and neck. Neck and
limbs are tested and rated separately, and scores range
from normal (score = 0) to severe (score = 4).
Bradykinesia is tested on finger tapping, hand move-
ments, pronation-supination movements of hands, toe
tapping, leg agility, and global spontaneity of movement
(body bradykinesia). Each limb is tested and rated separ-
ately evaluating speed, amplitude, hesitations, halts, and
decrementing amplitude. Body bradykinesia provides a
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and small amplitude and poverty of movement in gen-
eral. Scores range from normal (score = 0) to severe
(score = 4).
Postural stability is the examination of the response to
sudden body displacement produced by a quick, forceful
pull on the shoulders while the individual is standing
erect with eyes open and feet comfortably apart and par-
allel to each other. Scores range from normal (score = 0)
to severe (score = 4).
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